UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares gapped up prior to trading on Friday. The stock had previously closed at $236.49, but opened at $254.09. UCB shares last traded at $235.66, with a volume of 34 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on UCBJF. Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

UCB Trading Down 3.4%

The business’s fifty day moving average price is $260.58 and its 200-day moving average price is $283.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.